Vaccine wagers on coronavirus surface protein pay off
Jon Cohen
Abstract
Moderna reports early evidence of excellent efficacy, moving its mRNA candidate closer to widespread use.
Topics & Concepts
CoronavirusCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologySurface proteinBiologyMedicineOutbreakInfectious disease (medical specialty)Internal medicineDiseaseVirus-based gene therapy researchRNA Interference and Gene DeliveryCAR-T cell therapy research